Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Corrigendum to "Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma": [Ann Oncol 35 (2024) 1039-1047].
Kim TM, Taszner M, Novelli S, Cho SG, Villasboas JC, Merli M, Jiménez-Ubieto A, Tessoulin B, Poon LM, Tucker D, Walewski J, Yi S, Song Y, Chong G, Bachy E, Guidez S, Alonso A, Jagadeesh D, Zhang W, Magnano L, Iskierka-Jażdżwska E, Tani M, Shen B, Uppala A, Zhu M, Shariff S, Brouwer-Visser J, Chaudhry A, Mohamed H, Ambati S, Luminari S; ELM-2 Investigators. Kim TM, et al. Among authors: tessoulin b. Ann Oncol. 2024 Dec 2:S0923-7534(24)04945-7. doi: 10.1016/j.annonc.2024.11.009. Online ahead of print. Ann Oncol. 2024. PMID: 39627085 Free article. No abstract available.
Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy.
Camus V, Houot R, Brisou G, Tessoulin B, Bailly S, Sesques P, Decroocq J, Krzisch D, Oberic L, Lemonnier F, Bouabdallah K, Campidelli A, Tounes L, Abraham J, Herbaux C, Morschhauser F, Damaj GL, Guidez S, Carras S, Fornecker LM, Choquet S, Hermine O, Paillassa J, Chauchet A, Casasnovas O, Drieu La Rochelle L, Castilla-Llorente C, Joris M, Dupont V, Marquet A, Le Gouill S, Jardin F. Camus V, et al. Among authors: tessoulin b. Blood Adv. 2024 Oct 22;8(20):5371-5381. doi: 10.1182/bloodadvances.2024013726. Blood Adv. 2024. PMID: 39163620 Free PMC article.
Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma.
Kim TM, Taszner M, Novelli S, Cho SG, Villasboas JC, Merli M, Jiménez-Ubieto A, Tessoulin B, Poon LM, Tucker D, Walewski J, Yi S, Song Y, Chong G, Bachy E, Guidez S, Alonso A, Jagadeesh D, Zhang W, Magnano L, Iskierka-Jażdżewska E, Tani M, Shen B, Uppala A, Zhu M, Shariff S, Brouwer-Visser J, Chaudhry A, Mohamed H, Ambati S, Luminari S; ELM-2 Investigators. Kim TM, et al. Among authors: tessoulin b. Ann Oncol. 2024 Nov;35(11):1039-1047. doi: 10.1016/j.annonc.2024.08.2239. Epub 2024 Aug 13. Ann Oncol. 2024. PMID: 39147364 Free article. Clinical Trial.
Should We Reconsider Pneumocystis Pneumonia Presentation and Treatment According to Its Underlying Disease?: An Unsupervised Cluster Analysis of a Retrospective Multicenter Study.
Gaborit B, Lécuyer R, Issa N, Camou F, Lavergne RA, Gabriel F, Morio F, Canet E, Raffi F, Boutoille D, Cady A, Gousseff M, Crabol Y, Néel A, Tessoulin B; Prognostic Factors in Pneumocystis Pneumoniae (PRONOCYSTIS) Study Group. Gaborit B, et al. Among authors: tessoulin b. Chest. 2024 Oct;166(4):708-711. doi: 10.1016/j.chest.2024.04.038. Epub 2024 Jun 10. Chest. 2024. PMID: 38866071 Free article. No abstract available.
Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma.
Sarkozy C, Callanan M, Thieblemont C, Obéric L, Burroni B, Bouabdallah K, Damaj G, Tessoulin B, Ribrag V, Houot R, Morschhauser F, Griolet S, Joubert C, Cacheux V, Delwail V, Safar V, Gressin R, Cheminant M, Delfau-Larue MH, Hermine O, Macintyre E, Le Gouill S. Sarkozy C, et al. Among authors: tessoulin b. Blood. 2024 Jul 18;144(3):262-271. doi: 10.1182/blood.2024023944. Blood. 2024. PMID: 38669626 Free article. Clinical Trial.
Late Relapse after Allogeneic Stem Cell Transplantation in Patients Treated for Acute Myeloid Leukemia: Relapse Incidence, Characteristics, Role of Conditioning Regimen, and Outcome.
Antier C, Jullien M, Tessoulin B, Loirat M, Peterlin P, Garnier A, Le Bourgeois A, Chevallier P, Guillaume T. Antier C, et al. Among authors: tessoulin b. Cancers (Basel). 2024 Apr 5;16(7):1419. doi: 10.3390/cancers16071419. Cancers (Basel). 2024. PMID: 38611097 Free PMC article.
Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.
Iannitto E, Ferrero S, Bommier C, Drandi D, Ferrante M, Bouabdallah K, Carras S, Gini G, Camus V, Mancuso S, Marcheselli L, Ferrari A, Merli M, Tessoulin B, Stelitano C, Beldjord K, Roti G, Jardin F, Castagnari B, Palombi F, Baseggio L, Traverse-Glehen A, Tripodo C, Liberati AM, Parolini M, Usai S, Patti C, Federico M, Musso M, Ladetto M, Zucca E, Thieblemont C. Iannitto E, et al. Among authors: tessoulin b. Haematologica. 2024 Jul 1;109(7):2297-2302. doi: 10.3324/haematol.2023.284109. Haematologica. 2024. PMID: 38497158 Free PMC article. Clinical Trial. No abstract available.
77 results